In a call for public comment, the FDA believes that reducing excess opioid supplies can lower opioid misuse, abuse, and overdose.

The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.

Combining all three drugs can reduce claim closure rates to 58.3%, with average claim costs of $94,000.

Four research sites will test proven opioid prevention and treatment interventions, hoping to reduce overdose deaths by 40% over three years.

New changes to REMS safety programs will require stronger treatment documentation and oversight.

The workforce is aging, getting younger, and gaining more women, all at once. What does that mean for claims management?

Various state and local governments have sued drug developers for the harms of the opioid epidemic, and this could be the first of many settlements.

Demographic factors such as gender, ethnicity, socioeconomic status, age, and location can impact opioid risks.

Dr. Robert Goldberg and Sandy Shtab talk with Risk & Insurance about changing attitudes and policies around medical marijuana, its potential role in reducing reliance on opioids, and what this can mean for payers, employers, patients and PBMs.

A new JAMA study finds that increased county-level opioid marketing was tied to elevated overdose mortality.